Diaceutics CEO, Ryan Keeling, features in solli's October series on HCP and patient engagement. In the article Pharma Faces an Execution Gap Between Diagnosis and Treatment. How Can Marketers Close It?, Andrea Park explores why so many eligible patients don't reach the right therapy, and what pharma marketers can do about it.
The feature draws on the Diaceutics Strategic Collaboration Survey 2026. We asked 125 biopharma professionals how well their organizations move patients from diagnosis to treatment. They see it as a commercial priority, giving it an average score of 7.5/10 as a driver of future success. But they rate their ability to act on it lower: 5.2/10 for turning diagnostic insight into coordinated action, and 5.4/10 for visibility across the patient journey.
Ryan told solli: "Pharma doesn't have a data shortage, it has an execution problem."
Andrea's article goes on to look at how media strategy, HCP targeting and measurement may need to change, and why collaboration across the industry will be key.
Where are patients getting lost in your brand's pathway?
FAQS
What is the execution gap in pharma?
Why does diagnosis-to-treatment conversion matter for pharma marketers?
How can pharma marketers measure impact beyond reach?
What role does collaboration play in closing the execution gap?
What data do pharma marketers need to act sooner?
How can pharma marketers reach the right HCPs at the right time?
